In addition, previous studies have demonstrated that brusatol inhibits RCC progression by targeting the PTEN/PI3K/AKT signalling pathway,9 which motivated further investigation of the potential effects of brusatol. The gene discussed is AKT1; the disease is renal cell carcinoma.